Table 2.
Ref. | Year | No. of patients | MDFST (mo) | 3-ydfsr (%) | 5-ydfsr (%) | Factors associated with worse disease-free survival |
Elias et al[7] | 1998 | 1201 | NR | NR | 282 | NR |
Yedibela et al[9] | 2005 | 1501 | NR | NR | NR | NR |
Weitz et al[8] | 2005 | 141 | 17 | 30 | NR | Primary tumor, diseas-free interval ≤ 24 mo |
Adam et al[10] | 2006 | 1452 | 13 | 27 | 21 | NR |
Lendoire et al[11] | 2007 | 106 | NR | NR | NR | NR |
O'Rourke et al[12] | 2008 | 102 | 18 | 37 | 27 | Diameter of liver metastasis > 5 cm, extrahepatic nodal disease |
Groeschl et al[13] | 2012 | 420 | NR | NR | NR | NR |
Takemura et al[14] | 2013 | 145 | 10 | 21 | 18 | Blood transfusuion, preoperative chemotherapy |
Hoffmann et al[15] | 2015 | 150 | 21 | 36 | 29 | NR |
Schiergens et al[16] | 2016 | 167 | 15 | NR | NR | > 3 liver metastases, extrahepatic disease, residual tumor (R1,2) |
Patients with neuroendocrine tumors were excluded;
Results including neuroendocrine tumors. MDFST: Median disease-free survival time; ydfsr: Year disease-free survival ratio; NR: Not reported.